Microbot Medical (NASDAQ:MBOT) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Microbot Medical (NASDAQ:MBOT) released its earnings results on Friday. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01), FiscalAI reports. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.01 million.

Microbot Medical Price Performance

NASDAQ MBOT traded down $0.05 during mid-day trading on Friday, hitting $0.98. The company’s stock had a trading volume of 867,060 shares, compared to its average volume of 1,297,094. Microbot Medical has a 52-week low of $0.93 and a 52-week high of $2.85. The stock’s fifty day simple moving average is $1.17 and its two-hundred day simple moving average is $1.80. The firm has a market capitalization of $65.70 million, a P/E ratio of -4.08 and a beta of 1.07.

Wall Street Analyst Weigh In

MBOT has been the subject of a number of research analyst reports. UBS Group set a $2.50 price objective on shares of Microbot Medical in a research note on Friday, October 23rd. Citizens Jmp started coverage on shares of Microbot Medical in a research report on Friday, October 23rd. They issued a “market outperform” rating and a $2.50 target price on the stock. Zacks Research downgraded shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Weiss Ratings lowered shares of Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Finally, B. Riley Financial assumed coverage on shares of Microbot Medical in a research report on Friday, September 11th. They set a “buy” rating and a $4.00 price target for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.08.

Microbot Medical Company Profile

Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.